Company News

2021-08-24
ImmuneOnco Received NMPA Authorization to Proceed with 3 Phase Ib/IIa Clinical Trials of IMM01 Combined with Azacytitin, Rituximab and Inetetamab
August 25, 2021, Shanghai, China ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. ( hereinafter referred to as "ImmuneOnco") announced that 3 phase Ib/IIa trials of company’s lead drug candidate, IMM01, Fc fusion protein targeting CD47,the first in China, combined with Azacytitin for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), with Rituximab for relapsed/refractory B-cell lymphoma and with Inetetamab (CipterbinTM) in her2-positive solid tumors have been approved by the National Drug Products Administration (NMPA).
View more
2021-08-21
ImmuneOnco received FDA approval of IMM2902 as an Investigational New Drug (IND) in the United States
August 21, 2021, Shanghai, China. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") declared that the U.S. Food and Drug Administration (FDA) has granted permission to IMM2902, a bi-specific antibody-receptor recombinant protein targeting Human CD47xHER2 for HER2-expressing advanced solid tumors for the Investigational New Drug (IND) application in the United States.
View more
2021-08-18
ImmuneOnco Succesfully Finished First-in-Human Dosing of Its Bi-Specific Fusion Protein IMM2510
August 18, 2021, Shanghai, China. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that first-in-human (FIH) dosing of IMM2510, the second product of bi-specific antibodies in clinical stage, has been successfully finished.
View more
2021-07-26
Tracy Song appointed as Chief Financial Officer (CFO) of ImmuneOnco
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that Ms.Tracy(Ziyi) Song has been appointed as the Chief Financial Officer (CFO) of the company, reporting to Dr. Wenzhi Tian, Chairman and founder of ImmuneOnco. Ms. Song will be responsible for the IPO financial transactions and financial strategy of ImmuneOnco.
View more
2021-06-30
The Bi-specific CD47XHER2 fusion protein, IMM2902 approved for clinical trial by National Medical Products Administration (NMPA)
June 30, 2021, Shanghai, China. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that the first-in-Class drug candidate, Bi-specific recombinant fusion protein targeting human CD47and HER2 named IMM2902 received clinical trial approval from the National Medical Products Administration (NMPA).
View more
2021-03-05
ImmuneOnco received ‘Hi-Tech Enterprise Certificate’
On March 05, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter refer to as ImmuneOnco) announced receiving ‘Hi-Tech Enterprise Certificate’. This certificate is jointly issued by Shanghai Municipal Science and Technology Commission, Shanghai Municipal Finance Bureau and Shanghai Taxation Bureau of State Administration of Taxation.
View more
总计 62 1234567891011